CliniMACS® Cytokine Capture System (IFN-gamma) – Product Line

CliniMACS
®
Cytokine Capture System (IFN-gamma) – Product Line

Interferon-gamma (IFN-gamma) is a cytokine secreted by CD4
+
and CD8
+
memory and effector T cells upon antigenic restimulation.
The CliniMACS® Cytokine Capture System (IFN-gamma) – Product Line is comprised of the CliniMACS IFN-gamma Catchmatrix Reagent, consisting of CD45 antibodies conjugated to IFN-gamma specific antibodies, and the CliniMACS IFN-gamma Enrichment Reagent.
The CliniMACS IFN-gamma Enrichment Reagent consists of murine anti- IFN-gamma monoclonal antibodies conjugated to superparamagnetic iron dextran particles. The CliniMACS IFN- gamma Enrichment Reagent allows the magnetic selection of IFN-gamma–secreting cells.
One kit is suitable for processing up to 1 × 10
9
total cells.
Please inquire about required CliniMACS System components and accessories.

Disclaimer

The CliniMACS
®
System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for
in vitro
use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CliniMACS GMP MicroBeads are for research use and
ex vivo
cell processing only.
CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use.

Applications

The CliniMACS Cytokine Capture System (IFN-gamma) – Product Line allows for the concomitant enrichment of viable antigen-specific CD4
+
and CD8
+
IFN- gamma–secreting T cells.

Referenced literature

Antigen-specific CD4 and CD8 T cells can be enriched using the CliniMACS Cytokine Capture System (IFN-gamma)
1
.
A successful enrichment of T cells with the specificity for HCMV
2
, AdV
3
, EBV
4
, and
Aspergillus5
, as well as leukemia-reactive T cells
6
has been demonstrated.
Adoptively transferred antigen-specific T cells have been shown to restore protective immunity and control established AdV
7
, HCMV
8
, and EBV
9
infections after hematopoietic stem cell transplantations.
  • Selected references

    1. Campbell J.D. (2003) Detection and enrichment of antigen-specific CD4+ and CD8+ T cells based on cytokine secretion. Methods 31(2): 150-159
    2. Rauser G. et al. (2004)
      Rapid generation of combined CMV-specific CD4
      +
      and CD8
      +
      T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants.
      Blood 103(9): 3565-3572
    3. Feuchtinger, T. et al. (2008) Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J. Immunother. 31: 199-206
    4. Hammer, M. H. et al. (2007) Generation of EBV-specific T cells for adoptive immunotherapy: A novel protocol using formalin-fixed stimulator cells to increase biosafety. J. Immunother. 30: 817-824
    5. Beck et al. (2006)
      Generation of highly purified and functionally active human Tʜ1 cells against
      Aspergillus fumigatus
      .
      Blood 107: 2562-2569
    6. Jedema et al. (2007) Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. Clin. Cancer Res. 13: 636-643
    7. Feuchtinger, T. et al. (2006) Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br. J. Haematol. 134(1): 64-76
    8. Mackinnon et al. (2008) Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol. Dis. 40: 63-67
    9. Moosmann et al. (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115: 2960-2970
  • Selected references

  • Brochures and posters

  • Certificates

    Please follow this
    link
    to search for Certificates of Analysis (CoA) by lot number.
Product options: 1
EUR 2.745,00